Weesp, Netherlands

Herman H Van Stuivenberg

This inventor holds 18 USPTO granted patents and 1 published patent application, plus 6 CIPO patents and 4 EPO patents, primarily in Cannabinoid Receptor Modulators. Top assignees: Solvay Pharmaceuticals, B.v., Solvay Pharmaceuticals, Gmbh, Duphar International Research Bv. Active years: 1991-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Herman H Van Stuivenberg. Retrieved from https://idiyas.com/inventor/herman-h-van-stuivenberg

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 

% Patents Active = 11.1

 

 

Average Co-Inventor Count = 4.0

ph-index = 4

Forward Citations = 54(Granted Patents)


Company Filing History:


Years Active: 1991-2015

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
CB2 Receptor
Benzimidazolone
Quinazolinone
CB1 Antagonist
Neurotensin
Dihydro-Pyrazole
1H-Imidazole
Anti-Ulcer Activity
Receptor Agonists
2,3-Diaryl-Pyrazolidine
1,4-Diazepine
CB1 Agonist
18 patents (USPTO):Explore Patents

Title: Innovations of Herman H Van Stuivenberg

Introduction

Herman H Van Stuivenberg is a notable inventor based in Weesp, Netherlands. He has made significant contributions to the field of pharmaceuticals, particularly in the development of cannabinoid receptor modulators. With a total of 18 patents to his name, his work has had a considerable impact on medical research and treatment options.

Latest Patents

One of his latest patents involves 1H-imidazole derivatives as cannabinoid CB2 receptor modulators. This invention relates to a group of 1H-imidazole derivatives that act as modulators of cannabinoid CB receptors. The patent details methods for the preparation of these compounds, novel intermediates useful for their synthesis, and pharmaceutical compositions containing these derivatives as active ingredients. These compounds are particularly relevant for treating disorders associated with cannabinoid CB receptors. Another patent focuses on a group of novel 1H-imidazole derivatives, which are potent cannabinoid-CB receptor agonists, partial agonists, or antagonists. These compounds are useful for treating psychiatric and neurological disorders, as well as other diseases involving cannabinoid neurotransmission.

Career Highlights

Herman H Van Stuivenberg has worked with prominent companies in the pharmaceutical industry, including Solvay Pharmaceuticals B.V. and Solvay Pharmaceuticals GmbH. His experience in these organizations has allowed him to develop and refine his innovative ideas, contributing to advancements in medical treatments.

Collaborations

Throughout his career, Van Stuivenberg has collaborated with notable colleagues such as Josephus H M Lange and Cornelis G Kruse. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the quality of his inventions.

Conclusion

Herman H Van Stuivenberg's contributions to the field of pharmaceuticals through his innovative patents and collaborations have made a significant impact on medical research. His work continues to influence the development of treatments for various disorders, showcasing the importance of innovation in healthcare.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…